Nasdaq

SAB BIO Reports Positive Phase 1 Trial Results for SAB-142 in Type 1 Diabetes, Supporting Advancement to Phase 2b Development

SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
manilatimes

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
Nasdaq

SAB BIO Reports Q1 2025 Financial Results and Progress on SAB-142 for Type 1 Diabetes Treatment

SAB BIO, a clinical-stage biopharmaceutical company focused on developing immunotherapy for type 1 diabetes (T1D), announced its financial results for Q1 2025, highlighting substantial progress in its ...